Optum guides providers through important upcoming formulary updates
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
On December 17, 2020 - Amgen announced the FDA approval of Riabni (rituximab-arrx), a biosimilar to Genentech/Biogen’s Rituxan® (rituximab).
Download PDF
Return to publications
